Ebola Vaccine

The recent ebola outbreak in west Africa has stressed the need for advances in research to develop a vaccine against this deadly virus. Much progress has been made in pre-clinical and clinical studies and future vaccines for the ebola virus look promising. Here is the latest research on ebola vaccines.

August 4, 2020
Open Access

Current Approaches and Trends in Graduate Public Health Informatics Education in the United States: Four Case Studies from the Field

Online Journal of Public Health Informatics
Diane G SchwartzBrian E Dixon
July 24, 2020
Open Access

Luminore CopperTouch™ surface coating effectively inactivates SARS-CoV-2, Ebola and Marburg viruses in vitro

MedRxiv : the Preprint Server for Health Sciences
Emily MantloAlfred T Mitchell
August 5, 2020
Open Access

Nanotechnology-based antiviral therapeutics

Drug Delivery and Translational Research
Malobika Chakravarty, Amisha Vora
July 29, 2020

What's New in Vaccine Science

Primary Care
Margot Savoy
July 30, 2020
Open Access

Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature

The Western Journal of Emergency Medicine
Arif MusaDavid A Baron
August 5, 2020

Endo-Lysosomal Cation Channels and Infectious Diseases

Reviews of Physiology, Biochemistry and Pharmacology
Yu-Kai ChaoChristian Grimm
August 5, 2020

Identification and functional characterization of a novel C-type lectin from the kuruma shrimp, Marsupenaeus japonicus

Biochemical and Biophysical Research Communications
Jinbin ZhengJun Wang
July 19, 2020

Computational design of a potential multi-epitope subunit vaccine using immunoinformatics to fight Ebola virus

Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases
Ajinkya KadamPrakash Saudagar
August 5, 2020

COVID-19 in the geriatric population

International Journal of Geriatric Psychiatry
Justin RoyNitasa Sahu
August 1, 2020
Open Access

A flexible format LAMP assay for rapid detection of Ebola virus

PLoS Neglected Tropical Diseases
Laura C BonneyRoger Hewson
July 29, 2020

Investigating the binding affinity, interaction, and structure-activity-relationship of 76 prescription antiviral drugs targeting RdRp and Mpro of SARS-CoV-2

Journal of Biomolecular Structure & Dynamics
Sinthyia AhmedMohammad A Halim
July 21, 2020
Open Access

Annexin A2 depletion exacerbates the intracerebral microhemorrhage induced by acute rickettsia and Ebola virus infections

PLoS Neglected Tropical Diseases
Zhengchen SuBin Gong
July 24, 2020
Open Access

Activating NK- receptors, homing selectins and inhibitory Siglecs recognize EBOLA-GP and HPV-L1NK

BioRxiv : the Preprint Server for Biology
Mostafa JarahianC. Watzl
August 4, 2020

Safety of stent-assisted coiling for the treatment of wide-necked ruptured aneurysm: A systematic literature review and meta-analysis of prevalence

Interventional Neuroradiology : Journal of Peritherapeutic Neuroradiology, Surgical Procedures and Related Neurosciences
Shadi BsatIbrahim Omeis
July 30, 2020
Open Access

Drug discovery strategies for SARS-CoV-2

The Journal of Pharmacology and Experimental Therapeutics
Zeenat A ShyrW. Zheng

Sign up to follow this feed and discover related papers.

Related Feeds

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS therapies here.

Acute viral rhinopharyngitis

Acute viral rhinopharyngitis, also known as "common cold", is an acute, self-limiting viral infection of the upper respiratory tract involving the nose, sinuses, pharynx and larynx. Discover the latest research on acute viral rhinopharyngitis here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.


Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.


Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.


Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

© 2020 Meta ULC. All rights reserved